Search clinical trials for: LDX Placebo MAS-IR Placebo

Total 53882 results

Shire

Completed

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Attention-Deficit Hyperactivity Disorder

United States
Impax Laboratories, LLC

Completed

Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease

Parkinson's Disease

United States
NeuroDerm Ltd.

Active, not recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

United States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom
Stallergenes Greer

Completed

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

Rhinitis, Allergic, Perennial | House Dust Mite Allergy

France, United States
Bioxodes S.A.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

Healthy

Belgium
Dompé Farmaceutici S.p.A

Terminated

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

New-onset Type 1 Diabetes

United States, Belgium, Georgia, Germany, Italy, Serbia
LGD
ProRelix Services LLP

Active, not recruiting

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Sickle Cell Disease

India
Stallergenes Greer

Completed

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Primary Disease

France, Italy, Spain
Stallergenes Greer

Completed

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Allergic Rhinitis Due to Grass Pollens

United States
Landos Biopharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Ulcerative Colitis

United States, Ukraine
Yale University
CIRCUFIBER, Inc.

Completed

Infrared Wraps Effect on Oxygenation of Diabetics Arm, Feet and Lower Leg

Diabetes

United States
MapLight Therapeutics

Recruiting

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

United States, Australia, Canada
Galapagos NV

Completed

A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases

Healthy

Netherlands
Stallergenes Greer

Completed

Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

Allergy

France
Anji Pharma

Suspended

Investigational Study of Delayed Release Metformin (DREAM-T2D)

Diabetes Mellitus, Type 2

Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
Medical University of Lodz

Completed

Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis

Allergic Rhinitis

Poland
Stallergenes Greer

Completed

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Allergy

Germany
Stallergenes Greer

Completed

Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

Seasonal Allergic Rhinitis

Austria
Dompé Farmaceutici S.p.A

Terminated

Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. (CONSERVA)

Type 1 Diabetes

Italy
Dompé Farmaceutici S.p.A

Withdrawn

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Type I Diabetes

United States
Galapagos NV

Completed

A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects

Healthy

Belgium
Hoffmann-La Roche

Completed

A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers

Healthy Volunteer

New Zealand
Elcelyx Therapeutics, Inc.

Completed

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

Type 2 Diabetes Mellitus

United States, Puerto Rico
Bristol-Myers Squibb

Completed

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

South Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
Stallergenes Greer

Completed

Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

Allergy
GlaxoSmithKline

Completed

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

United States
Bayer
Merck Sharp & Dohme LLC; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF (VITALITY-HFpEF)

Chronic Heart Failure With Preserved Ejection Fraction

Spain, United States, Belgium, Singapore, Taiwan, Canada, Japan, Italy, Austria, Bulgaria, Germany, Greece, Israel, Poland, Portugal, Hungary, Russian Federation, Argentina, Colombia, Malaysia, South Africa
Shire

Completed

Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

ADHD

United States
Impax Laboratories, LLC

Completed

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

Parkinson's Disease (Disorder)

United States, Czechia, France, Italy, Spain, Germany, Poland, United Kingdom
Q32 Bio Inc.

Recruiting

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

Atopic Dermatitis

United States
Zevra Therapeutics
Rho, Inc.

Active, not recruiting

Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

Idiopathic Hypersomnia

United States
Aldeyra Therapeutics, Inc.

Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Atopic Asthma

Canada
Q32 Bio Inc.

Completed

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

Safety Issues

Australia
Impax Laboratories, LLC

Completed

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States
Neurovance, Inc.

Completed

A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020

Normal, Healthy Volunteers

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Healthy Participants | Atopic Dermatitis Patients

China
Q32 Bio Inc.
Innovaderm Research Inc.

Active, not recruiting

Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata (SIGNAL-AA)

Alopecia Areata

United States
Aldeyra Therapeutics, Inc.

Completed

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

Chronic Cough

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Covid19

United States
Jazz Pharmaceuticals

Completed

A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

Narcolepsy

United States
Jazz Pharmaceuticals

Completed

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

Narcolepsy

United States
ZYUS Life Sciences Inc.
Novotech (Australia) Pty Limited; ZYUS Life Sciences Australia Pty Ltd

Completed

Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation (HOPE)

Healthy | Osteoarthritis

Australia
Impax Laboratories, LLC

Completed

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
R&G Pharma Studies Co.,Ltd.

Completed

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profile in Healthy Chinese Volunteers of TG-2349

Healthy Chinese Volunteers

China
EnnovaBio Australia Pharmaceuticals Pty Ltd

Not yet recruiting

A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects

Healthy
Shanghai Jiatan Pharmatech Co., Ltd

Completed

Sudapyridine (WX-081) in Healthy Volunteers

Healthy

China
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers

Healthy Participants

Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers

Healthy Volunteers

Canada
Maxinovel Pty., Ltd.

Not yet recruiting

A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects

Alopecia Areata
Inmagene LLC

Completed

Study to Evaluate IMG-004 in Healthy Participants

Healthy Participants

United States

3

Subscribe